ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2004
The economic burden of supportive care of cancer patients.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 61 citations in OpenAlex.
- Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study.Journal of gynecologic oncology · 2025Trial
- Comparing the effects of saffron and Mucosamin® spray on oral mucositis induced by radiotherapy: A randomized controlled clinical trial.Avicenna journal of phytomedicine · 2026Article
- Resource utilization and cost of diarrhea-related hospitalizations among cancer patients in Jordan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis.Frontiers in pharmacology · 2024Article
- Cancer survival stories: Perception, creation, and potential use case.Health expectations : an international journal of public participation in health care and health policy · 2023Article
- Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer.Frontiers in oncology · 2023Article
- Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.Journal of managed care & specialty pharmacy · 2022Article
- What Oncologists Must Account for: The Financial Burden of Cancer-Associated Symptom Relief.JCO oncology practice · 2022Article
- Impact of severe oral mucositis in pediatric cancer patients on resource utilization and cancer treatment plans.International journal of clinical pharmacy · 2021Article
- Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.Annals of translational medicine · 2021Article
- Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2- Advanced or Metastatic Breast Cancer: A US Payer Perspective.Frontiers in medicine · 2021Article
- Mouthwash Containing Vitamin E, Triamcinolon, and Hyaluronic Acid Compared to Triamcinolone Mouthwash Alone in Patients With Radiotherapy-Induced Oral Mucositis: Randomized Clinical Trial.Frontiers in oncology · 2021Article
- Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue.BMC cancer · 2020Article
- The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study.International journal of health policy and management · 2018Article
- The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue.PharmacoEconomics · 2013Review
- A prospective study to assess in vivo optical coherence tomography imaging for early detection of chemotherapy-induced oral mucositis.Lasers in surgery and medicine · 2013Article
- Febrile mucositis in haematopoietic SCT recipients.Bone marrow transplantation · 2009Article
- Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2008Article
- Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome.Integrative cancer therapiesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
goals of workEconomic and regulatory healthcare policy is limited by the lack of population-based information on the cost of supportive care of cancer patients. The goal of this study was to estimate these costs and to explore the impact of these costs on policy decisions. PATIENTS AND
methodsWe identified estimates of the cost of outpatient and inpatient supportive care from published reports in the literature. The range of these costs (from lowest to highest) is described for each supportive care condition. These estimates were supplemented by computing the cost of all hospitalizations for these conditions in Texas between June 2000 and December 2001. Medicare payments were used to estimate average reimbursement. Costs (not charges) were standardized to 2002 US dollars using the consumer price index for medical care and Medicare's cost-to-charge ratio for Texas. MAIN
resultsInpatient care for most conditions exceeded 7,000 US dollars per episode. Our population-based estimates of the cost of care were similar to literature-based estimates, except in the case where conditions could be managed in the outpatient setting. Average Medicare payments were often far lower than the estimated cost of care. For example, the estimated cost of hospitalization for management of diarrhea was 6,616 US dollars while the average Medicare payment was only 2,809 US dollars.
conclusionsMany supportive care interventions are quite expensive. In an environment focused on cost containment, a risk-based approach to expensive supportive care treatments is essential. Further study of the cost effectiveness of supportive care management strategies is indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.